-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Continues to Innovate: The Antiepileptic Drug Lacosamide Tablets Approved
Category:
Time：2021-10-11
Just after the National Day holiday, on October 11, Shijiazhuang No.4 Pharmaceutical Co., Ltd. received more good news: the company’s lacosamide tablets (50 mg and 100 mg) have been granted drug registration certificates by the National Medical Products Administration and are deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. The approval of this product is of great significance for further enriching the company’s solid dosage form product line.
It is understood that lacosamide is a sodium channel modulator that can regulate the activity of sodium channels, effectively reducing the influx of sodium ions and lowering neuronal excitability, thereby achieving the therapeutic goal of treating epilepsy. It is indicated for monotherapy and combination therapy in patients aged 4 years and older with partial-onset seizures.
Lacosamide is an antiepileptic drug originally developed by UCB Pharma of Belgium, featuring a novel dual mechanism of action. In 2020, global sales of lacosamide reached US$1.656 billion, and the market is currently experiencing rapid growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code